Atlas Trials

Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer

Clinical trial NCT01827267 · COMPLETED

Trial details

NCT number
NCT01827267
Sponsor
Puma Biotechnology, Inc.
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
HER2-mutant Non-Small Cell Lung Cancer
Start date
2013-07-01
Primary completion
2016-09-20
Enrollment
62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.